Identification of sitagliptin binding proteins by affinity purification mass spectrometry: Sitagliptin binding proteins identified by affinity purification mass spectrometry
Type 2 diabetes mellitus (T2DM) is recognized as a serious public health concern with increasing incidence. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin has been used for the treatment of T2DM worldwide. Although sitagliptin has excellent therapeutic outcome, adverse effects are observed...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827809/ https://www.ncbi.nlm.nih.gov/pubmed/36239351 http://dx.doi.org/10.3724/abbs.2022142 |